Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.

Company Announcements

Protolabs Reports Financial Results for the First Quarter of 2026

Record Quarterly Revenue of $139.3 Million, a 10.4% Increase Year-Over-Year

GAAP Earnings Per Share of $0.33, Non-GAAP Earnings Per Share of $0.54

MINNEAPOLIS--(BUSINESS WIRE)--May 1, 2026-- Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights:

  • Revenue was a record $139.3 million, a 10.4% increase over the first quarter of 2025.
    • CNC machining revenue grew 19.7% year-over-year.
    • Revenue per customer contact increased 20.4% year-over-year.
  • Net income was $8.1 million, or $0.33 per diluted share, compared to $3.6 million, or $0.15 per diluted share, in the first quarter of 2025.
  • Non-GAAP net income was $13.1 million, or $0.54 per diluted share, compared to $8.1 million, or $0.33 per diluted share, in the first quarter of 2025. See “Non-GAAP Financial Measures” below.

"Protolabs started 2026 very strong, delivering another record revenue quarter. We achieved double‑digit revenue growth, gross margin expansion, and operating expense leverage. These results reflect strong demand for Protolabs' digital manufacturing services, and disciplined execution across the business," said President and Chief Executive Officer Suresh Krishna. "We’re making continued progress across our strategic pillars while strengthening the organization to support long‑term growth and scalability."

Additional First Quarter 2026 Financial Highlights:

  • Non-GAAP gross margin was 46.2% of revenue, compared to 44.8% of revenue in the first quarter of 2025. See “Non-GAAP Financial Measures” below.
  • Adjusted EBITDA was $22.8 million, or 16.3% of revenue, compared to $17.4 million, or 13.8% of revenue in the first quarter of 2025. See “Non-GAAP Financial Measures” below.
  • Cash generated from operations was $17.5 million.
  • Cash and investments balance was $158.0 million as of March 31, 2026.

"First quarter results reflect the strength of our operating model, delivering record revenue alongside improved profitability," said Dan Schumacher, Chief Financial Officer. "We generated strong cash flow and reported our highest non‑GAAP earnings per share in more than five years, while continuing to invest in our strategic pillars and transformational initiatives to support long‑term profitable growth."

Financial Guidance and Outlook:

  • In fiscal year 2026, Protolabs expects to generate revenue growth between 6% and 8%.
  • In the second quarter of 2026, the Company expects to generate revenue between $140.0 million and $148.0 million.
  • In the second quarter of 2026, the Company expects diluted net income per share between $0.29 and $0.37, and non-GAAP diluted net income per share between $0.50 and $0.58. See "Non-GAAP Financial Measures" below.

Non-GAAP Financial Measures

The Company has included non-GAAP revenue growth by region and by service line that excludes the impact of changes in foreign currency exchange rates (collectively, “non-GAAP revenue growth”). Management believes these metrics, when viewed in conjunction with the comparable GAAP metrics, are useful in evaluating the underlying business trends and ongoing operating performance of the Company.

The Company has included earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency, restructuring and transformation costs, and benefits related to exit and disposal activities (collectively, “Adjusted EBITDA”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin (“EBITDA margin”) and EBITDA margin, adjusted for stock-based compensation expense, unrealized (gain) loss on foreign currency, restructuring and transformation costs, and benefits related to exit and disposal activities (collectively, “Adjusted EBITDA margin”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense and amortization expense, in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense, restructuring and transformation costs, and benefits related to exit and disposal activities (collectively, “non-GAAP operating margin”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has included non-GAAP net income and non-GAAP net income per share, in each case, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, restructuring and transformation costs, and benefits related to exit and disposal activities (collectively, “non-GAAP net income”), in this press release to provide investors with additional information regarding the Company’s financial results.

The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP net income per share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by service line, and Adjusted EBITDA and Adjusted EBITDA margin, the most directly comparable measures calculated and presented in accordance with GAAP. These non-GAAP measures are used by the Company’s management and board of directors to understand and evaluate operating performance and trends, provide useful measures for period-to-period comparisons of the Company’s business, and in determining executive and senior management incentive compensation. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in our condensed consolidated financial statements and are subject to inherent limitations. Investors should review the reconciliations of non-GAAP financial measures to the comparable GAAP financial measures that are included in this press release.

Conference Call

The Company has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook today, May 1, 2026 at 8:30 a.m. EDT. To access the call in the U.S. please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media-server.com/mmc/p/9bgsjeh5/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.

About Protolabs

Protolabs is the world’s fastest manufacturing service enabling companies across every industry to streamline production of quality parts throughout the entire product life cycle. From custom prototyping to end-use production, we support product developers, engineers, and supply chain teams along every phase of their manufacturing journey. Get started now at protolabs.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.

 

Proto Labs, Inc.
Condensed Consolidated Balance Sheets
(In thousands)

 

 

 

 

 

March 31,
2026

 

December 31,
2025

 

(Unaudited)

 

 

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

123,973

 

$

110,826

Short-term marketable securities

 

12,307

 

 

17,297

Accounts receivable, net

 

85,553

 

 

78,962

Inventory

 

14,871

 

 

14,401

Prepaid expenses and other current assets

 

10,698

 

 

9,590

Income taxes receivable

 

1,175

 

 

2,465

Total current assets

 

248,577

 

 

233,541

 

 

 

 

Property and equipment, net

 

209,463

 

 

215,261

Goodwill

 

273,991

 

 

273,991

Other intangible assets, net

 

17,527

 

 

18,612

Long-term marketable securities

 

21,721

 

 

14,308

Operating lease assets

 

2,490

 

 

2,836

Finance lease assets

 

357

 

 

424

Other long-term assets

 

4,442

 

 

4,442

Total assets

$

778,568

 

$

763,415

 

 

 

 

Liabilities and shareholders' equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

19,625

 

$

15,104

Accrued compensation

 

17,258

 

 

23,674

Accrued liabilities and other

 

32,595

 

 

26,783

Current operating lease liabilities

 

1,037

 

 

1,155

Current finance lease liabilities

 

207

 

 

286

Total current liabilities

 

70,722

 

 

67,002

 

 

 

 

Long-term operating lease liabilities

 

1,377

 

 

1,606

Long-term deferred tax liabilities

 

18,949

 

 

16,598

Other long-term liabilities

 

4,394

 

 

4,277

 

 

 

 

Shareholders' equity

 

683,126

 

 

673,932

Total liabilities and shareholders' equity

$

778,568

 

$

763,415

 

 

 

 

 

 

 

 

Proto Labs, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

2025

 

Revenue

 

 

 

Injection Molding

$

51,068

 

$

48,723

 

CNC Machining

 

63,245

 

 

52,843

 

3D Printing

 

20,465

 

 

20,194

 

Sheet Metal

 

4,351

 

 

4,211

 

Other Revenue

 

207

 

 

234

 

Total Revenue

 

139,336

 

 

126,205

 

 

 

 

 

Cost of revenue

 

75,744

 

 

70,507

 

Gross profit

 

63,592

 

 

55,698

 

 

 

 

 

Operating expenses

 

 

 

Marketing and sales

 

24,780

 

 

23,749

 

Research and development

 

10,540

 

 

10,609

 

General and administrative

 

17,012

 

 

16,848

 

Restructuring and transformation costs

 

1,421

 

 

 

Benefits related to exit and disposal activities

 

 

 

(39

)

Total operating expenses

 

53,753

 

 

51,167

 

Income from operations

 

9,839

 

 

4,531

 

Other income, net

 

1,478

 

 

1,454

 

Income before income taxes

 

11,317

 

 

5,985

 

Provision for income taxes

 

3,206

 

 

2,386

 

Net income

$

8,111

 

$

3,599

 

 

 

 

 

Net income per share:

 

 

 

Basic

$

0.34

 

$

0.15

 

Diluted

$

0.33

 

$

0.15

 

 

 

 

 

Shares used to compute net income per share:

 

 

 

Basic

 

23,835,612

 

 

24,135,320

 

Diluted

 

24,287,260

 

 

24,435,844

 

 

 

 

 

Proto Labs, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

 

2025

 

Operating activities

 

 

 

Net income

$

8,111

 

 

$

3,599

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

8,073

 

 

 

8,694

 

Stock-based compensation expense

 

3,219

 

 

 

3,992

 

Deferred taxes

 

2,390

 

 

 

(1,552

)

Interest on finance lease obligations

 

3

 

 

 

6

 

Impairments related to exit and closure of facilities

 

 

 

 

219

 

Gain on disposal of property and equipment

 

(139

)

 

 

 

Other

 

(172

)

 

 

43

 

Changes in operating assets and liabilities

 

(3,949

)

 

 

3,378

 

Net cash provided by operating activities

 

17,536

 

 

 

18,379

 

 

 

 

 

Investing activities

 

 

 

Purchases of property, equipment and other capital assets

 

(3,540

)

 

 

(1,262

)

Proceeds from sales of property, equipment and other capital assets

 

1,279

 

 

 

 

Purchases of marketable securities

 

(9,007

)

 

 

(6,552

)

Proceeds from maturities of marketable securities

 

6,500

 

 

 

4,905

 

Net cash used in investing activities

 

(4,768

)

 

 

(2,909

)

 

 

 

 

Financing activities

 

 

 

Proceeds from issuance of common stock from equity plans

 

3,608

 

 

 

287

 

Purchases of shares withheld for tax obligations

 

(2,871

)

 

 

(1,248

)

Repurchases of common stock

 

 

 

 

(20,890

)

Principal repayments of finance lease obligations

 

(79

)

 

 

(76

)

Net cash provided by (used in) financing activities

 

658

 

 

 

(21,927

)

Effect of exchange rate changes on cash and cash equivalents

 

(279

)

 

 

78

 

Net increase (decrease) in cash and cash equivalents

 

13,147

 

 

 

(6,379

)

Cash and cash equivalents, beginning of period

 

110,826

 

 

 

89,071

 

Cash and cash equivalents, end of period

$

123,973

 

 

$

82,692

 

 

 

 

 

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Net Income and Non-GAAP Net Income per Share
(In thousands, except share and per share amounts)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

 

2025

 

Non-GAAP net income, adjusted for stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, restructuring and transformation costs and benefits related to exit and disposal activities

 

 

 

GAAP net income

$

8,111

 

 

$

3,599

 

Add back:

 

 

 

Stock-based compensation expense

 

3,219

 

 

 

3,992

 

Amortization expense

 

913

 

 

 

908

 

Unrealized (gain) loss on foreign currency

 

 

 

 

(135

)

Restructuring and transformation costs

 

1,421

 

 

 

 

Benefits related to exit and disposal activities

 

 

 

 

(39

)

Total adjustments 1

 

5,553

 

 

 

4,726

 

Income tax benefits on adjustments 2

 

(586

)

 

 

(242

)

Non-GAAP net income

$

13,078

 

 

$

8,083

 

 

 

 

 

 

 

 

 

Non-GAAP net income per share:

 

 

 

Basic

$

0.55

 

 

$

0.33

 

Diluted

$

0.54

 

 

$

0.33

 

 

 

 

 

Shares used to compute non-GAAP net income per share:

 

 

 

Basic

 

23,835,612

 

 

 

24,135,320

 

Diluted

 

24,287,260

 

 

 

24,435,844

 

 

 

 

 

1 Stock-based compensation expense, amortization expense, unrealized (gain) loss on foreign currency, restructuring and transformation costs and benefits related to exit and disposal activities were included in the following GAAP consolidated statement of operations categories:

 

Three Months Ended
March 31,

 

 

2026

 

 

2025

 

 

 

 

 

Cost of revenue

$

736

 

$

802

 

 

 

 

 

Marketing and sales

 

705

 

 

778

 

Research and development

 

428

 

 

625

 

General and administrative

 

2,263

 

 

2,695

 

Restructuring and transformation costs

 

1,421

 

 

 

Benefits related to exit and disposal activities

 

 

 

(39

)

Total operating expenses

 

4,817

 

 

4,059

 

 

 

 

 

Other income, net

 

 

 

(135

)

Total adjustments

$

5,553

 

$

4,726

 

 

 

 

 

2 For the three months ended March 31, 2026 and 2025, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the respective period.

 

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Gross Margin
(In thousands)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

 

2025

 

Revenue

$

139,336

 

 

$

126,205

 

Gross profit

 

63,592

 

 

 

55,698

 

GAAP gross margin

 

45.6

%

 

 

44.1

%

Add back:

 

 

 

Stock-based compensation expense

 

394

 

 

 

460

 

Amortization expense

 

342

 

 

 

342

 

Total adjustments

 

736

 

 

 

802

 

Non-GAAP gross profit

$

64,328

 

 

$

56,500

 

Non-GAAP gross margin

 

46.2

%

 

 

44.8

%

 

 

 

 

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Operating Margin
(In thousands)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

 

2025

 

Revenue

$

139,336

 

 

$

126,205

 

Income from operations

 

9,839

 

 

 

4,531

 

GAAP operating margin

 

7.1

%

 

 

3.6

%

Add back:

 

 

 

Stock-based compensation expense

 

3,219

 

 

 

3,992

 

Amortization expense

 

913

 

 

 

908

 

Restructuring and transformation costs

 

1,421

 

 

 

 

Benefits related to exit and disposal activities

 

 

 

 

(39

)

Total adjustments

 

5,553

 

 

 

4,861

 

Non-GAAP income from operations

$

15,392

 

 

$

9,392

 

Non-GAAP operating margin

 

11.0

%

 

 

7.4

%

 

 

 

 

Proto Labs, Inc.
Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA
(In thousands)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

 

2025

 

Revenue

$

139,336

 

 

$

126,205

 

GAAP net income

 

8,111

 

 

 

3,599

 

GAAP net income margin

 

5.8

%

 

 

2.9

%

Add back:

 

 

 

Amortization expense

$

913

 

 

$

908

 

Depreciation expense

 

7,160

 

 

 

7,786

 

Interest income, net

 

(1,253

)

 

 

(1,108

)

Provision for income taxes

 

3,206

 

 

 

2,386

 

EBITDA

 

18,137

 

 

 

13,571

 

EBITDA Margin

 

13.0

%

 

 

10.8

%

Add back:

 

 

 

Stock-based compensation expense

 

3,219

 

 

 

3,992

 

Unrealized (gain) loss on foreign currency

 

 

 

 

(135

)

Restructuring and transformation costs

 

1,421

 

 

 

 

Benefits related to exit and disposal activities

 

 

 

 

(39

)

Total adjustments

 

4,640

 

 

 

3,818

 

Adjusted EBITDA

$

22,777

 

 

$

17,389

 

Adjusted EBITDA Margin

 

16.3

%

 

 

13.8

%

 

 

 

 

Proto Labs, Inc.
Comparison of GAAP to Non-GAAP Revenue Growth by Region
(In thousands)
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31, 2026

 

Three Months Ended
March 31, 2025

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

United States

$

112,127

 

$

 

 

$

112,127

 

$

100,267

 

11.8

%

 

11.8

%

Europe

 

27,209

 

 

(2,157

)

 

 

25,052

 

 

25,938

 

4.9

 

 

(3.4

)

Total revenue

$

139,336

 

$

(2,157

)

 

$

137,179

 

$

126,205

 

10.4

%

 

8.7

%

 

 

 

 

 

 

 

 

 

 

 

 

1 Revenue for the three months ended March 31, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2 This column presents the percentage change from GAAP revenue for the three months ended March 31, 2025 to GAAP revenue for the three months ended March 31, 2026.

3 This column presents the percentage change from GAAP revenue for the three months ended March 31, 2025 to non-GAAP revenue for the three months ended March 31, 2026 (as recalculated using the foreign currency exchange rates in effect during the three months ended March 31, 2025) in order to provide a constant-currency comparison.

 

 

Proto Labs, Inc.
Comparison of GAAP to Non-GAAP Revenue Growth by Service Line
(In thousands)
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31, 2026

 

Three Months Ended
March 31, 2025

 

%

Change2

 

% Change

Organic3

 

GAAP

 

Foreign

Currency1

 

Non-GAAP

 

GAAP

 

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

Injection Molding

$

51,068

 

$

(631

)

 

$

50,437

 

$

48,723

 

4.8

%

 

3.5

%

CNC Machining

 

63,245

 

 

(1,114

)

 

 

62,131

 

 

52,843

 

19.7

 

 

17.6

 

3D Printing

 

20,465

 

 

(368

)

 

 

20,097

 

 

20,194

 

1.3

 

 

(0.5

)

Sheet Metal

 

4,351

 

 

(42

)

 

 

4,309

 

 

4,211

 

3.3

 

 

2.3

 

Other Revenue

 

207

 

 

(2

)

 

 

205

 

 

234

 

(11.5

)

 

(12.4

)

Total revenue

$

139,336

 

$

(2,157

)

 

$

137,179

 

$

126,205

 

10.4

%

 

8.7

%

 

 

 

 

 

 

 

 

 

 

 

 

1 Revenue for the three months ended March 31, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates.

2 This column presents the percentage change from GAAP revenue for the three months ended March 31, 2025 to GAAP revenue for the three months ended March 31, 2026.

3 This column presents the percentage change from GAAP revenue for the three months ended March 31, 2025 to non-GAAP revenue for the three months ended March 31, 2026 (as recalculated using the foreign currency exchange rates in effect during the three months ended March 31, 2025) in order to provide a constant-currency comparison.

 

 

 

Proto Labs, Inc.
Customer Contact Information
(In thousands, except customer contacts and per customer contact amounts)
(Unaudited)

 

 

 

 

 

Three Months Ended
March 31,

 

 

2026

 

 

2025

Revenue

$

139,336

 

$

126,205

Customer contacts

 

19,826

 

 

21,627

Revenue per customer contact1

$

7,028

 

$

5,836

 

 

 

 

1 Revenue per customer contact is calculated using the revenue recognized during the respective period divided by the actual number of customer contacts served during the same period. Customer contacts are product developers, engineers, procurement and supply chain professionals and other individuals who place an order, and that order is shipped and invoiced during the period. The Company believes revenue per customer contact is useful to investors in evaluating the underlying business trends and ongoing operating performance of the Company.

 

Proto Labs, Inc.
Reconciliation of GAAP to Non-GAAP Guidance
(Unaudited)

 

 

 

 

 

Q2 2026 Outlook

 

Low

 

High

GAAP diluted net income per share

$

0.29

 

$

0.37

Add back:

 

 

 

Stock-based compensation expense

 

0.16

 

 

0.16

Amortization expense

 

0.03

 

 

0.03

Restructuring and transformation costs

 

0.02

 

 

0.02

Unrealized (gain) loss on foreign currency

 

0.00

 

 

0.00

Total adjustments

 

0.21

 

 

0.21

Non-GAAP diluted net income per share

$

0.50

 

$

0.58

 

 

 

 

 

Investor Relations Contacts
Protolabs
Ryan Johnsrud, 612-225-4873
Sr. Manager – Investor Relations and Corporate Development
ryan.johnsrud@protolabs.com

Gateway Group, Inc.
949-574-3860
PRLB@gateway-grp.com

Media Contact
Protolabs
Brent Renneke, 763-479-7704
Corporate Communications Manager
brent.renneke@protolabs.com

Source: Proto Labs, Inc.